KBI Biopharma

We're proud to announce that KBI Biopharma been recognized as a leader in the 2024 CDMO Leadership Awards across all six categories. Presented by Outsourced Pharma and Life Science Connect, with Industry Standard Research (ISR) Reports’ Contract Manufacturing Quality Benchmarking annual online surveys, the awards recognize the CDMOs that meet or exceed their customers' expectations. Learn more about the awards and see photos from last night's ceremony in New York City: https://lnkd.in/ghwt_nSe #KBIBiopharma #CDMO #CDMOLeadershipAwards 

LGBTQ Life Sciences Group is meeting in Fort Collins next month! 🌈 Join us on Thursday, August 29th at 5:30 p.m. for this free event to connect with others in the community and build your network. Each attendee receives a complimentary drink thanks to our community sponsor KBI Biopharma. Save your spot now! RSVP Today: https://lnkd.in/g36_7Ubj Life Sciences LGBTQ Meet & Greet Thursday, August 29th 5:30 - 7:30 p.m. Location to be Announced | Fort Collins, CO #lifesciences #lgbtq #Fortcollins Colorado State University

Meet William Behnke, an Associate Scientist who has been on the KBI Biopharma team for five years! Will serves as a point of contact and project lead in the Characterization Services Department of Analytical and Formulation Sciences (AFS). In his day-to-day, he designs studies, executes lab work, performs data analysis, and consults with clients. Will enjoys conducting mass spectrometry analysis but also likes his program management responsibilities outside the lab. The collaboration opportunities are what Will enjoys most about KBI. "It's an honor to work alongside so many talented scientists to ultimately provide patients with the treatments they need," he shares. Will stays active when he's not conducting experiments; he enjoys rock climbing, powerlifting, and skiing. He also enjoys playing fetch with his cat, Mora, and traveling with his partner. #EmployeeSpotlight #TeamMemberTuesday #KBIBiopharma

KBI Biopharma today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company, following a successful FDA inspection. “As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. Read the full release: https://lnkd.in/gEaitQ2s #KBIBiopharma #CDMO ##Biopharma 

Developing a therapeutic mAb? Using Beacon®, our experts pick and load the highest producing pools in our Beacon® chips for export and clone isolation. This cutting-edge technology provides visual proof of monoclonality, ensuring your cell line is clonal in origin before moving to RCB. This method of monoclonality proof is commonly accepted as the highest proof by regulatory agencies, offering an even more robust confirmation of monoclonality than the traditional statistical calculation from FACS or limited dilution methodologies. Learn more: https://hubs.la/Q02cy6hM0

A huge thank you to KBI Biopharma for welcoming St. Vrain Valley Schools P-TECH interns and providing them with an exceptional learning experience. Your dedication to nurturing young talent and offering real-world insights has made a profound impact on their learning journey. #PTECH #ThankYouKBI #STEMEducation #Internship #FutureLeaders #IndustryPartnership #COBioScienceInstitute #ClassroomCampusCareer

We’re looking forward to BIO Asia-Taiwan next week! If you're planning to attend, visit us at booth M520 to discuss our next-generation CDMO services with Toshihiro (Toshi) Ogawa. See you in Taipei! Learn more or schedule a meeting here: https://lnkd.in/gbT2VVwT #bioasiataiwan

Last chance to register for tomorrow's Outsourced Pharma webinar hosted by our experts Erik Nordwald, Marlee Paulson, and Shaunak Uplekar. See you there!

WEBINAR TOMORROW! On July 18th, watch KBI Biopharma demonstrate how their mammalian and microbial expression platforms can accelerate the development and manufacturing of mAbs, multispecific Abs, ADCs, fusion proteins, and other recombinant therapeutic proteins. You'll also learn more about their cutting-edge digital data access tool and how it can enhance data access and collaboration during process development. 📅 Register today: https://lnkd.in/eVFitAp8 🗣 Speakers: Shaunak Uplekar, Associate Director, Upstream Process Development Erik Nordwald, Associate Director, Cell Line Development Marlee Paulson, PROGRAMview Product Owner

What is the future of microbial expression systems? 🦠 Microbial expression systems are widely used to manufacture diagnostic and therapeutic proteins. However, the commercialization success rate for new drug developments is less than 3%, partly due to high development and manufacturing costs, long turnaround times, and challenging product safety profiles. 💸 CDMOs, including KBI, are jumping in to update microbial expression systems to surpass the modest yields of traditional E. coli models. KBI Biopharma has developed PUREcoli, a microbial expression system incorporating over 1,000 gene edits to enhance protein production. 📈 Learn more about it in our latest article! ⬇️ https://lnkd.in/d-KT-xbg #biotechinnovation #proteinproduction #therapeuticproteins #CDMOs #drugdevelopment #biomanufacturing #biotechresearch #biotechindustry